The Monitoring Illicit Substance Use (MISUse) Consortium: A Study Protocol for Investigating Low Prevalence Substance Use Behaviours in Population Cohort Studies

<u>Christopher J Greenwood</u>^{1,2,3}, Primrose Letcher ^{1,2,3}, Esther Laurance ¹, Joseph M Boden ⁴, James Foulds ⁴, Elizabeth A Spry ^{1,2,3}, Jessica A Kerr ^{2,3,4}, John W Toumbourou ¹, Jessica Heerde ^{2,3,5}, Catherine Nolan ^{1,6}, Yvonne Bonomo ^{7,8}, Delyse M Hutchinson ^{1,2,3,9}, Tim Slade ¹⁰, Craig A Olsson ^{1,2,3} Deakin University, Geelong, Australia, School of Psychology, Faculty of Health, Centre for Social and Early Emotional Development
Murdoch Children's Research Institute, Centre for Adolescent Health, Melbourne, Australia
The University of Melbourne, Department of Paediatrics, Royal Children's Hospital, Australia
Department of Psychological Medicine, University of Otago Christchurch, Christchurch New Zealand
The University of Melbourne, Department of Social Work, Melbourne, Australia
The Department of Education. Victorian Government, Australia
The University of Melbourne, Department of General Practice, Faculty of Medicine, Dentistry & Health Sciences, Melbourne, Australia
St Vincent's Health, Department of Addiction Medicine, Melbourne, Australia
National Drug and Alcohol Research Centre, Faculty of Medicine, University of New South Wales, Sydney, Australia
The Matilda Centre for Research in Mental Health and Substance Use, University of Sydney, NSW, Australia

abis

C

()

Т




Monitoring Illicit Substance Use Consortium

Introduction Background

 Global burden of disease estimates suggest that the impact of illicit substance use is increasing worldwide.¹

Methods Participants

 The Christchurch Health and Development Study (CHDS; est. 1977, Christchurch, New Zealand) –
N=1,265 from infancy to adulthood (24 waves).



- In Australasia, illicit substance use is within the top 10 leading causes of disease burden and its impact has increased.¹
- Multi-wave, prospective cohort studies are essential to advance understanding of the natural history, antecedents, and consequences.
- However, the low population prevalence of illicit substance use makes lifecourse studies difficult.²
- Solution? Maximise the value of illicit substance use data collected across multiple cohort studies using integrative data analysis. ^{3,4}

Aims

To pool data across four of the

- The Australian Temperament Project (ATP; est. 1983, Victoria, Australia) – N=2,443 from infancy to adulthood (16 waves).
- The Victorian Adolescent Health Cohort Study (VAHCS; est. 1992, Victoria, Australia) – N=1,943 from adolescence to adulthood (11 waves).
- The International Youth Development Study (IYDS, Australian sample; est.
 2002, Victoria, Australia) – N=2,884 from childhood to adulthood (10 waves).

Measures (Figure 1):


- Cannabis, amphetamine, cocaine,


longest running cohort studies in our region to examine: (1) the natural history, (2) antecedents, and (3) consequences of illicit substance use from adolescence to adulthood ecstasy, hallucinogens, opioids.

 Assessments vary across 'ever', 'yearly', 'monthly', 'weekly', 'daily'

Data (Figure 2)

- Clear patterns of increased use from adolescence and adulthood.
- Cannabis use: 27% and 39% in adolescence and young adulthood, respectively.
- Non-cannabis use: 1-4% to 1-20% in adolescence and young adulthood, respectively.





Current examinations

- Descriptive epidemiology examine patterns of illicit substance use behaviour across developmental periods.
- Causal modelling examine associations between amphetamine use and mental health problems across adolescence and young adulthood.

Conclusions

- The MISUse consortium builds on the strength of four long-running prospective cohort studies across Australia and New Zealand.
- Analyses are directly informed through close working relationship with translational partners in clinical practice

Figure 2: Developmental patterns across integrated data

and government.

 Variations in assessments of substance use, antecedents, and consequences across the cohort studies will require

careful harmonisation going forward.

Interested in collaborating?

Contact: christopher.greenwood@deakin.edu.au.



References

1 GBD 2019 Risk Factor Collaborators. (2020). Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet, 396(10258), 1223–1249. https://doi.org/10.1016/S0140-6736(20)30752-2

2 Degenhardt, L., Stockings, E., Patton, G., Hall, W. D., & Lynskey, M. (2016). The increasing global health priority of substance use in young people. The Lancet Psychiatry, 3(3), 251–264. https://doi.org/10.1016/S2215-0366(15)00508-8

3 Curran, P. J., & Hussong, A. M. (2009). Integrative data analysis: The simultaneous analysis of multiple data sets. Psychological Methods, 14(2), 81–100. <u>https://doi.org/10.1037/a0015914</u> 4 O'Connor, M., Spry, E., Patton, G., Moreno-Betancur, M., Arnup, S., Downes, M., Goldfeld, S., Burgner, D., & Olsson, C. A. (2022). Better together: Advancing life course research through multi-cohort analytic approaches. Advances in Life Course Research, 53, 100499. <u>https://doi.org/10.1016/j.alcr.2022.100499</u>



